Exelixis, Inc.  

(Public, NASDAQ:EXEL)   Watch this stock  
Find more results for EXEL
8.68
+0.09 (1.05%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.62 - 8.74
52 week 3.55 - 8.74
Open 8.67
Vol / Avg. 0.00/6.33M
Mkt cap 2.01B
P/E     -
Div/yield     -
EPS -0.90
Shares 228.74M
Beta 2.10
Inst. own 79%
Aug 3, 2016
Q2 2016 Exelixis Inc Earnings Release - 4:00PM EDT - Add to calendar
Aug 3, 2016
Q2 2016 Exelixis Inc Earnings Call - 2:00PM EDT - Add to calendar
Jun 5, 2016
Exelixis Inc Investor/Analyst Briefing to Review Cabozantinib Data at the American Society of Clinical Oncology (ASCO) Annual Meeting - Webcast
May 26, 2016
Exelixis Inc Annual Shareholders Meeting (Estimated)
May 25, 2016
Exelixis Inc Annual Shareholders Meeting
May 10, 2016
Exelixis Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
May 4, 2016
Q1 2016 Exelixis Inc Earnings Call - Webcast
May 4, 2016
Q1 2016 Exelixis Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -397.66% -456.63%
Operating margin -318.50% -326.65%
EBITD margin - -320.06%
Return on average assets -59.66% -51.78%
Return on average equity - -
Employees 115 -
CDP Score - -

Address

210 E Grand Ave
SOUTH SAN FRANCISCO, CA 94080-4811
United States - Map
+1-650-8377000 (Phone)
+1-650-8378300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Michael M. Morrissey Ph.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Christopher J. Senner Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Gisela M. Schwab M.D. President, Product Development and Medical Affairs and Chief Medical Officer
Bio & Compensation  - Reuters
Peter Lamb Ph.D. Executive Vice President - Scientific Strategy, Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Jeffrey J Hessekiel Executive Vice President, General Counsel
Age: 45
Bio & Compensation  - Reuters
Pamela A. Simonton J.D. Executive Vice President
Age: 64
Bio & Compensation  - Reuters
Deborah Burke Senior Vice President - Finance, Controller
Age: 59
Bio & Compensation  - Reuters
Charles M. Cohen Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Carl B. Feldbaum Esq. Independent Director
Age: 72
Bio & Compensation  - Reuters